Early in the pandemic, researchers began exploring various avenues to repurposing drugs for COVID-19.
There are many paths to repurposing, including high-throughput drug screening, which uses automated methods to screen thousands or even millions of molecules for targeted biological activity in a disease of interest. Other approaches include focusing on a certain biological mechanism of action (like testing other antivirals in COVID); combing through clinical trial data and public records; or, in the case of sildenafil citrate (Viagra), incidental clinical observation. (See
MedPage Today s full story on how drug repurposing is gaining momentum as demand for a COVID pill grows.)
email article
So far in the pandemic, support for research on drug repurposing particularly for inexpensive generics has not played a huge role in finding new treatments for COVID-19, but that appears to be changing.
Critics charge that drug repurposing is like looking for a needle in a haystack. It does not always work, and can raise false hopes and waste resources. In a March 7 interview with
60 Minutes, for instance, NIH director Francis Collins, MD, PhD, said drug repurposing is only going to work if you re kind of lucky, because you re basically picking things that were developed for a different disease.
Published: Feb 25, 2021
HALIFAX, Nova Scotia (BUSINESS WIRE) Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced additional details on its webinar series examining major trends in the global infectious disease landscape. The first event, scheduled for March 3 at 1:00 p.m. ET, will feature Dr. Scott Gottlieb, Dr. Syra Madad, and Dr. Josh Schimmer. The panel will discuss the need for investing in an arsenal of treatments, preventatives, and public health policies as part of pandemic response planning.
Speakers will also discuss the current state of the pandemic response, what may happen next, and what is required to fully address both COVID-19, as well as potential future infectious outbreaks. The live webcast will include a Q&A session. Appili plans to announce future events and speakers in the series throughout the year.
Sunday, January 03, 2021 by: Divina Ramirez
Bypass censorship by sharing this link:
https://www.afinalwarning.com/482957.html (Natural News) Scientists worldwide are still testing numerous drugs that can be repurposed for treating COVID-19. But one antiparasitic drug called Ivermectin is being touted as a very promising medicine for the disease.
During a recent Senate hearing, physicians called on the government to swiftly review the expansive medical evidence on Ivermectin as an early treatment for COVID-19.
The hearing held Tuesday, Dec. 8, was the latest effort by the Republican chairman of the homeland security committee, Sen. Ron Johnson of Wisconsin, to discuss early treatment options for COVID-19 in the hopes of reducing hospitalizations and preventing deaths.
Dr. Reddyâs files application for Reeqonus tablets to treat COVID-19 in Canada
Dr. Reddyâs, alongside Global Response Aid and Appili Therapeutics, has filed an application on behalf of Reeqonus (favipiravir) tablets in Canada.
âOur outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation, said Mitch Wilson, CEO of GRA. The filing is a testimony to our commitment of bringing a potential solution to COVID-19 for the Canadian population.â
The companies have filed a motion for the tablets to be used for the acute treatment of mild to moderate COVID-19 in adult patients under Health Canadaâs Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.